drugset
drugset / Trial / NCT03333928

A POC and Dose-Ranging Study of HTD1801 in PSC Patients

NCT03333928 ↗

Phase 2 Completed 59 enrolled HighTide Biopharma Pty Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study was a dose-ranging, 18-week study comparing two doses of HTD1801 (500 mg BID and 1000 mg BID) to placebo in adult subjects with PSC.

Timeline

Start
2018-02-09
Primary completion
2020-04-30
Completion
2020-08-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator berberine ursodeoxycholate Small molecule 500 mg —
Comparator berberine ursodeoxycholate Small molecule 1000 mg —

Indications

primary sclerosing cholangitis